The SCORED trial further reinforced the consistency of these salutary effects by showing a similarly large (33%) relative risk reduction in hospitalization for HF and urgent visits for HF with the dual SGLT1/2 inhibitor sotagliflozin [7]. Here, SLC5A1 is linked to hydrops fetalis.